Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ray Borrow

Showing results (91-100 of 403) with videos related to

Pageof 41
Sort By:
Clinical and Vaccine Immunology : CVI|June 1, 2012
Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introductionDavid A Ishola, Ray Borrow, Helen Findlow, et al.
The Journal of Infection|October 4, 2015
The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme--New challenges for public healthShamez N Ladhani, Helen Campbell, Sydel R Parikh, et al.
Vaccine|September 4, 2020
Broad vaccine protection against Neisseria meningitidis using factor H binding proteinJamie Findlow, Christopher D Bayliss, Peter T Beernink, et al.
The Pediatric Infectious Disease Journal|June 12, 2018
Characteristics of Children With Invasive Pneumococcal Disease After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine in England and Wales, 2010-2016Ashley Makwana, Carmen Sheppard, Ray Borrow, et al.
Clinical and Vaccine Immunology : CVI|April 22, 2011
Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding proteinJay Lucidarme, Lionel Tan, Rachel M Exley, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|January 10, 2019
Serogroup C <i>Neisseria meningitidis</i> disease epidemiology, seroprevalence, vaccine effectiveness and waning immunity, England, 1998/99 to 2015/16Helen Findlow, Helen Campbell, Jay Lucidarme, et al.
The Journal of Infection|June 26, 2013
Added value of PCR-testing for confirmation of invasive meningococcal disease in EnglandEllen Heinsbroek, Shamez Ladhani, Steve Gray, et al.
Clinical and Vaccine Immunology : CVI|March 11, 2011
Results from a randomized clinical trial of coadministration of RotaTeq, a pentavalent rotavirus vaccine, and NeisVac-C, a meningococcal serogroup C conjugate vaccineTimo Vesikari, Aino Karvonen, Ray Borrow, et al.
Vaccine|May 31, 2015
Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workersJamie Findlow, Xilian Bai, Helen Findlow, et al.
The Lancet. Infectious Diseases|February 13, 2019
Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trialsMichael White, Olubukola Idoko, Samba Sow, et al.
Pageof 41

Showing results (91-100 of 403) with videos related to

Sort By:
Pageof 41
Clinical and Vaccine Immunology : CVI|June 1, 2012
Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introductionDavid A Ishola, Ray Borrow, Helen Findlow, et al.
The Journal of Infection|October 4, 2015
The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme--New challenges for public healthShamez N Ladhani, Helen Campbell, Sydel R Parikh, et al.
Vaccine|September 4, 2020
Broad vaccine protection against Neisseria meningitidis using factor H binding proteinJamie Findlow, Christopher D Bayliss, Peter T Beernink, et al.
The Pediatric Infectious Disease Journal|June 12, 2018
Characteristics of Children With Invasive Pneumococcal Disease After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine in England and Wales, 2010-2016Ashley Makwana, Carmen Sheppard, Ray Borrow, et al.
Clinical and Vaccine Immunology : CVI|April 22, 2011
Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding proteinJay Lucidarme, Lionel Tan, Rachel M Exley, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|January 10, 2019
Serogroup C <i>Neisseria meningitidis</i> disease epidemiology, seroprevalence, vaccine effectiveness and waning immunity, England, 1998/99 to 2015/16Helen Findlow, Helen Campbell, Jay Lucidarme, et al.
The Journal of Infection|June 26, 2013
Added value of PCR-testing for confirmation of invasive meningococcal disease in EnglandEllen Heinsbroek, Shamez Ladhani, Steve Gray, et al.
Clinical and Vaccine Immunology : CVI|March 11, 2011
Results from a randomized clinical trial of coadministration of RotaTeq, a pentavalent rotavirus vaccine, and NeisVac-C, a meningococcal serogroup C conjugate vaccineTimo Vesikari, Aino Karvonen, Ray Borrow, et al.
Vaccine|May 31, 2015
Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workersJamie Findlow, Xilian Bai, Helen Findlow, et al.
The Lancet. Infectious Diseases|February 13, 2019
Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trialsMichael White, Olubukola Idoko, Samba Sow, et al.
Pageof 41